| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Panel offers proactive drug monitoring for IBD
Answers from the Lab
Therapeutic drug monitoring for patients with inflammatory bowel disease (IBD) has evolved. In this test-specific episode of the "Answers From the Lab" podcast, Maria Willrich Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' infliximab/adalimumab panel takes a proactive approach.
The test measures both drug concentration and antidrug antibodies in a single panel, to support improved clinical outcomes. "We appreciate that for some patients, proactive monitoring plays a significant role in helping to manage IBD early in the treatment course," Dr. Snyder says.
Clinical decision-making for patients with IBD can be complex. "Our test results will include a panel interpretation with comments to help the provider understand how to best act on the findings related to the antidrug antibody test in the presence of drug," Dr. Willrich says.
Mayo Clinic Laboratories continues to offer reflex testing, a two-step process that measures drug levels and antibodies in response to evidence of active disease. "Having a reflex test and the proactive panel provides versatility for physicians responding to their patients' needs," Dr. Willrich says.
Listen to learn more about Mayo Clinic Laboratories' infliximab/adalimumab panels.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
